- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00663247
Mechanistic Randomized Controlled Trial (RCT) of Mesalazine in Symptomatic Diverticular Disease
Mechanistic Randomized Controlled Trial of Mesalazine in Symptomatic Diverticular Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diverticular disease affects two thirds of the elderly population in the United Kingdom. Only a small fraction of individuals with diverticulosis develop symptoms, perhaps 1 in 10, for reasons which are not well understood. The symptoms however are quite disabling as we found in a recent survey which indicated that around 36% suffered recurrent abdominal pain. Surprisingly, given the severity of the disability there has been very little research into the factors predicting the development of painful diverticular disease. Recent studies have indicated however that there may be an inflammatory component since the best predictor of recurrent abdominal pain is a previous episode of acute diverticulitis.
Just what initiates an attack of acute diverticulitis is poorly understood but may include the inspissation of fecal material in the diverticulum which then leads to pressure on the lining epithelium and a break down of barrier function. This allows colonic bacteria to enter the lamina propria where they cause acute inflammation, attracting pus cells from the circulating blood and creating micro-abscesses. The resolution of this involves fibrosis and scaring together with muscular hypertrophy which may well lead to secondary motor abnormalities. Patients with symptomatic diverticular disease are known to have higher intraluminal pressures, both at baseline and in response to stimuli such as a meal or prostigmine.
A recent report in which patients admitted with acute diverticulitis were followed for two years found that a very high proportion of such individuals subsequently develop recurrent chronic abdominal pain. Recent work has indicated that this leaves a permanent change in mucosal innervation. Markers of nerve injury including galanin and substance P are upregulated in patients with symptoms as opposed to those without. This is the first time that an objective marker has been shown to distinguish patients on the basis of symptoms.
While acute diverticulitis may be the initiating insult, a chronic low level inflammation may also be required to maintain visceral hypersensitivity. Where detailed quantitative histology has been performed in diverticular disease, some individuals have been identified with a lymphocytic infiltration. In other circumstances, chronic inflammation sensitises mucosal nerves and is associated with visceral hypersensitivity, something which has also been noted in symptomatic diverticular disease.
Whether anti-inflammatory agents could reverse this process is as yet unknown but there are currently available safe and effective treatments for inflammatory bowel disease such as 5 amino-salicylic acid or budesonide which might well be effective and allow further evaluation of the role of low grade inflammation in symptomatic diverticular disease.
This study aims to investigate the inflammatory, neurological and symptomatic effects of mesalazine in diverticular disease.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Nottinghamshire
-
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
- NIHR Biomedical Research Unit, Nottingham University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Symptomatic diverticular disease with short lived recurrent abdominal pain on 3 or more days a month.
- 18 - 85 years of age.
- Signed informed consent
- Presence of at least one diverticulum in the left colon
Exclusion Criteria:
- Pregnant or lactating women.
- Severe co-morbidity, alcoholism or drug dependence or inability to give informed consent.
- Contraindications to use of Mesalazine as detailed in SmPC.
- Inability to stop NSAIDs (non-steroidal anti-inflammatory agents) or long term antibiotics.
- The use of specific concomitant medications as detailed in the section below.
- Presence of other gastrointestinal inflammatory conditions such as ulcerative colitis, Crohn's disease and Coeliac disease.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: A
|
3 grams daily for 3 months
Other Names:
|
Placebo Comparator: B
placebo used as control for comparison with active drug
|
3 grams daily for 3 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Difference in galanin expression in mucosal nerves from 0 to 12 weeks
Time Frame: 12 weeks
|
12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: RC Spiller, Prof, Nottingham University Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Gastrointestinal Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Pathological Conditions, Anatomical
- Diverticulum
- Diverticular Diseases
- Diverticulosis, Colonic
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Mesalamine
Other Study ID Numbers
- 07057
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diverticulosis, Colonic
-
Dr. Falk Pharma GmbHCompletedColonic DiverticulosisGermany
-
Saint Joseph Mercy Health SystemCompletedRectal Cancer | Colon Cancer | Colonic DiverticulosisUnited States
-
Saint Joseph Mercy Health SystemUnknownRectal Cancer | Colon Cancer | Colonic DiverticulosisUnited States
-
Saint Joseph Mercy Health SystemUnknownRectal Cancer | Colon Cancer | Colonic DiverticulosisUnited States
-
Groupe Hospitalier de la Rochelle Ré AunisMedtronicCompleted
-
Emmaus Medical, Inc.Completed
-
University of ReadingRoyal Berkshire HospitalUnknownDiverticulosis, Colonic | Microbiota
-
Assaf-Harofeh Medical CenterCompletedDiverticulitis | Diverticulosis, Colonic | Abdominal AdhesionIsrael
-
Centre Hospitalier Universitaire de NīmesCompletedColonic Neoplasms | Diverticulosis, Colonic
-
University of Roma La SapienzaUnknownDiverticulosis, Colonic | Diverticular Disease of ColonItaly
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States